Category Archives: USTR 301 report

‘Big Pharma’ backs Trump’s Asia trade squeeze

Source: ASIA TIMES | May 03, 2018 US President Donald Trump’s administration stands accused of deploying bullying tactics to promote greater market access for American pharmaceutical companies by stifling the production and distribution of more affordable, and usually totally legal, … Continue reading

Posted in Special 301 report, US Pressure, USTR 301 report | Leave a comment

LIES, DISTORTIONS, AND FALSE PROMISE: THE U.S. POSITION ON COMPULSORY LICENSES IN THE 2018 SPECIAL 301 REPORT

Source: infojustice.org | May 1, 2018 Every year since the late 1980s, the U.S. has published a Special 301 Watchlist targeting countries that U.S. intellectual property-based industries, like Big Pharma, complain about. Once again the U.S. is unbelievably duplicitous in its 2018 … Continue reading

Posted in Special 301 report, USTR, USTR 301 report | Leave a comment

USTR Priority Watch List calls out countries for protecting public health

Source: MSF Access | April 27, 2018 NEW YORK, APRIL 27, 2018-The Office of the United States Trade Representative (USTR) released its annual “Special 301 Report” today, which reviews countries based on their intellectual property (IP) rights protection and enforcement. … Continue reading

Posted in Special 301 report, USTR, USTR 301 report | Leave a comment

30+ Civil Society Orgs to USTR: Stop Threatening to Block Colombia’s OECD Accession over Pharma/Biotech Lobby Interests

Source: Knowledge Ecology International | March 20, 2018 A broad international coalition of over 30 human rights organizations, including some across the United States and Latin America, have come together to ensure that providing access to health care doesn’t come at … Continue reading

Posted in Uncategorized, USTR, USTR 301 report | Leave a comment

New Government Report Affirms India’s Patient-First Commitment on Pharma Patents

A government review says it is well within its rights to put Indian patients and the Indian generic pharmaceuticals industry first. As various countries await the US’s ‘Special 301 report’, where the US government discusses intellectual property negotiations with other … Continue reading

Posted in Indian Patent Law, Patent, Uncategorized, USTR, USTR 301 report | Leave a comment

US continue to bully India – Place India again in Special 301 Priority Watch List 2017

Yet again, USTR places India on its Priority Watch List in Special report 301 stating the lack of sufficient measurable improvements to its IP framework that negatively affects U.S. right holders across the world.  It points out that India support … Continue reading

Posted in Sec 3 (d), Special 301 report, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized, USTR, USTR 301 report | Leave a comment

Panel Rejects Eli Lilly Claim Over Canadian Patent Law, Orders Company to Pay Millions in Costs

In the early 1990s, Eli Lilly applied for patent protection in Canada for two chemical compounds, olanzapine and atomoxetine. The company had already obtained patents over the compounds, but asserted that it had evidence to support new uses for the … Continue reading

Posted in Investor state dispute, NAFTA, Special 301 report, Uncategorized, USTR, USTR 301 report | Leave a comment